3. Survey Component of the CDC's Prevention Marketing Initiative Local Demonstration Site Project Evaluation —NEW— The Centers for Disease Control and Prevention, National Center for HIV, STD, and TB Prevention, Division of HIV/AIDS Prevention, Behavioral Intervention Research Branch is planning to conduct a cross-sectional tracking study as part of the evaluation of a five-city HIV prevention demonstration program. The program involves the integration of social marketing strategies and community participation in an effort to develop and implement HIV prevention activities.

Charged with developing programs for those 25 years of age and younger, community groups in the local demonstration sites chose to segment the target audience even further, and to mount a variety of types of interventions. Decisions about segmentation and the nature of local interventions were based on formative research conducted in each community. It is hoped that this demonstration project will result in reductions in HIV risk behavior among members of the target audiences, as well as in enhanced collaboration among individuals and organizations in the participating communities.

As part of the evaluation of the effectiveness of the interventions, questionnaire data will be collected in three of the demonstration communities. These data will be collected at four time points over a two year period after prevention activities and message campaigns are launched. Baseline survey data have been collected recently under OMB No.0920-0343 (Evaluation of the National AIDS Information and Education Program Activities). The total annual burden hours are 4,260.

<table>
<thead>
<tr>
<th>Respondents</th>
<th>Number of respondents</th>
<th>Number of responses/respondent</th>
<th>Average burden/response (in hrs.)</th>
<th>Total burden (in hrs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility Screening</td>
<td>157,680</td>
<td>1</td>
<td>0.01667</td>
<td>2,628</td>
</tr>
<tr>
<td>Consent</td>
<td>5,768</td>
<td>1</td>
<td>0.05</td>
<td>289</td>
</tr>
<tr>
<td>Young People under 25 years of age in targeted prevention program communities</td>
<td>3,504</td>
<td>1</td>
<td>0.3833</td>
<td>1,343</td>
</tr>
</tbody>
</table>


Wilma G. Johnson,
Acting Associate Director for Policy Planning And Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97-6887 Filed 3-18-97; 8:45 am]
BILLING CODE 4163-18-P

Meeting Announcement

The National Center for Environmental Health (NCEH) of the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Preventing Birth Defects Due to Thalidomide Exposure.

Time and date: 8 a.m.-5 p.m., March 26, 1997.

Place: Sheraton Colony Square Hotel, 188 14th Street, NE, Atlanta, Georgia 30361.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 75 people. Registration is not required.

Purpose: The meeting will enable academic and public health professionals to discuss strategies to prevent birth defects due to exposure to thalidomide and other human teratogens. Thalidomide, a potent human teratogen, is now available as an investigational drug in the USA. Although the drug is currently being considered for approval only for the treatment of leprosy, its potential applications appear to be numerous. This meeting will bring together leaders from the fields of birth defects research, clinical practice, bioethics, and public health to review existing strategies for limiting intrauterine exposure to human teratogens, and to discuss and provide individual input on new approaches for preventing birth defects due to future teratogens such as thalidomide.

Matters to be discussed: Agenda items will include presentations on the following topics: (1) Assessment of the Accutane Pregnancy Prevention Program, (2) use and limitations of drug registries, (3) contraception efficacy, (4) ethical issues on teratogen exposure, and (5) measures to assure appropriate use of pharmaceuticals. Group discussions on strategies for health care provider education, patient education, and appropriate use of pharmaceuticals will follow the presentations. Written materials may be submitted to CDC until March 21, 1997, for distribution to meeting participants.

Agenda items are subject to change as priorities dictate.

FOR FURTHER INFORMATION CONTACT: Dwight Jones, Division of Birth Defects and Developmental Disabilities, NCEH, CDC, 4770 Buford Highway, NE, M/S F-45, Atlanta, Georgia 30341–3724, telephone 770/488–7160, Fax 770/488–7197.


Carolyn J. Russell,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 97–7017 Filed 3–18–97; 8:45 am]
BILLING CODE 4163-18-P

Food and Drug Administration

Request for Nominations: Appointment of a Nonvoting Representative of Industry Interests on a Public Advisory Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting nominations for a nonvoting industry representative to serve on the Nonprescription Drugs Advisory Committee in the Center for Drug Evaluation and Research. This vacancy will occur on June 1, 1997.

FDA has a special interest in ensuring that women, minority groups, and individuals with disabilities are adequately represented on advisory committees and, therefore, the agency encourages nominations of appropriately qualified candidates from these groups.

DATES: Nominations should be received by April 18, 1997.

ADDRESSES: All nominations and curricula vitae for the industry representative should be sent to Andrea G. Neal (address below).

FOR FURTHER INFORMATION CONTACT: Andrea G. Neal, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FAX 301–443–0699.

SUPPLEMENTARY INFORMATION: FDA is requesting that any industry organization interested in participating in the selection of an appropriate nonvoting member to represent industry interests should send a letter to the contact person (address above). After 30 days, a letter will be sent to each organization that has made a nomination, and to those organizations indicating an interest in participating in the selection process, together with a complete list of all such organizations and the nominees. This letter will state that it is the responsibility of each organization indicating an interest in participating in the selection process to consult with the others in selecting a